Caerus Investment Advisors LLC Invests $713,000 in United Therapeutics Corporation $UTHR

Caerus Investment Advisors LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,464 shares of the biotechnology company’s stock, valued at approximately $713,000.

Several other hedge funds also recently made changes to their positions in the business. NDVR Inc. grew its stake in shares of United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares during the last quarter. First Financial Bankshares Inc boosted its holdings in shares of United Therapeutics by 0.3% in the fourth quarter. First Financial Bankshares Inc now owns 21,034 shares of the biotechnology company’s stock worth $10,249,000 after buying an additional 55 shares during the period. Keel Point LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth about $266,000. MIdWestOne Financial Group Inc. boosted its holdings in shares of United Therapeutics by 13.3% in the fourth quarter. MIdWestOne Financial Group Inc. now owns 10,704 shares of the biotechnology company’s stock worth $5,216,000 after buying an additional 1,258 shares during the period. Finally, Stirlingshire Investments Inc. acquired a new position in shares of United Therapeutics in the fourth quarter worth about $236,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on UTHR shares. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

UTHR stock opened at $545.40 on Friday. The stock has a market cap of $23.15 billion, a P/E ratio of 20.13, a P/E/G ratio of 1.77 and a beta of 0.57. The firm has a 50 day simple moving average of $567.24 and a 200 day simple moving average of $521.17. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 624,984 shares of company stock worth $352,682,302 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.